Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,525 recalls · Class III, newest first

Class III · Low risk

Absorica (Isotretinoin)

Subpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring.

Terminated Wrong potency / content Sun Pharmaceutical Industries, Inc. NDC 10631-117-31 D-1207-2019
Class III · Low risk

Amlodipine and Olmesartan Medoxomil Tablets

Discoloration: This product is being recalled due to a confirmed pharmacist report that tablets from this lot were a pink color instead of cream (peach).

Terminated Failed specification Aurobindo Pharma USA Inc. NDC 65862-855-30 D-0289-2019
Class III · Low risk

Aprepitant Capsules

Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.

Terminated Failed specification Glenmark Pharmaceuticals Inc., USA NDC 68462-583-40 D-0349-2019
Class III · Low risk

Norepinephrine 8 mg

Incorrect excipient: Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium Chloride

Terminated Other QuVa Pharma, Inc. D-0295-2019
Class III · Low risk

Nitrofurantoin Capsules USP

Cross contamination with other products: This sub-recall is being initiated in support of the recall by the manufacturer (Sandoz) dated 11/1/18, which included lots that were repackaged by American Health Packaging. Sandoz stated that "These lots are being recalled due to the potential presence of unrelated ingredients (i.e. traces of active ingredients of Benazepril, Haloperidol and Perphenazine), which were identified through a manufacturing investigation."

Terminated Cross-contamination American Health Packaging NDC 68084-446-01 D-0273-2019
Class III · Low risk

AMITIZA (lubiprostone)

Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testing.

Terminated Impurity / degradation Takeda Development Center Americas, Inc. NDC 64764-080-60 D-0286-2019
Class III · Low risk

Megestrol Acetate Oral Suspension

Failed Stability Specifications: Out-of-Specification results obtained for particle size distribution during stability testing.

Terminated Stability / shelf life Breckenridge Pharmaceutical, Inc. D-0279-2019
Class III · Low risk

Curaplex Epi Safe Kit

Labeling: Incorrect or missing Lot and/or Exp Date:The Kit is incorrectly labeled as expiring May 2018 however the correct expiration date is May 2019. In addition, device component (syringe) lacks 510(k) clearance.

Terminated Labeling / mix-up Bound Tree Medical, LLC D-0379-2019
Class III · Low risk

Metoprolol Tartrate Injection

Failed pH Specifications: High Out-of-Specification results for pH were obtained during stability testing.

Terminated Failed specification RemedyRepack Inc. NDC 70518-0868-00 D-0245-2019
Class III · Low risk

Metoprolol Tartrate Injection

Failed pH Specifications: Upward shift in the pH of the solution within the shelf life of the impacted lots.

Terminated Failed specification Baxter Healthcare Corporation D-0222-2019
Class III · Low risk

Testosterone Topical Solution

Defective Container: Repetitive complaints received indicating pump not working.

Terminated Packaging defect Lupin Pharmaceuticals Inc. NDC 68180-943-11 D-0087-2019
Class III · Low risk

Temozolomide capsules

Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing.

Terminated Dissolution failure Amerigen Pharmaceuticals Inc. NDC 43975-253-14 D-0249-2019

Recalls by year